Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Prostate Cancer
•
Medical Oncology
How many cycles of docetaxel do you give to patients with metastatic castration resistant prostate cancer?
Answer from: Medical Oncologist at Community Practice
Toxicity with Neuropathy can be a major problem in the elderly population.
Sign in or Register to read more
5102
Related Questions
What is the optimal sequence of available therapies in patients with BRCA+/HRR mCRPC after progression on first line combinations?
Under what circumstances would you treat prostate cancer without a biopsy?
Is there adequate evidence for the use of PARPi in combination with ARSI for BRCA+/HRR mutated mCRPC as compared to sequential therapy?
How do you manage de novo high volume mCSPC with both BRCA2 mutation and MSI-H on somatic testing?
How would you approach treating a patient with prostate adenocarcinoma with urothelial features?
For patients with oligo-progressive prostate cancer fit for metastasis-directed therapy but ineligible for radiotherapy or surgery, how do you decide between the types of ablation available?
Are there any scenarios in which you would consider use of PARPi in the upfront mCSPC setting rather than reserving for CRPC?
Are there any contraindications to Pluvicto therapy you personally use, given that there are none directly provided by the manufacturer?
Is there any way to safely treat patients with mCRPC with 177-Lu PSMA who are on hemodialysis?
What is your experience with Pylarify vs. Posluma PSMA PET for prostate cancer and is one preferred over the other?